CD14, CD44, CD115, and CD163 are well captured in the blood and brains of patients without GBM, providing a potential avenue for noninvasive biospecimen analysis and immune signature monitoring in GBM (Figure 3A). This evidence concerns the gene CD163 and glioblastoma.